Press release

Release
27.10.2020

VALBIOTIS presents the first market data on untreated LDL-hypercholesterolemia for TOTUM-070, and announces the initiation of the Phase II clinical study HEART

Download
Release
05.10.2020

VALBIOTIS integrates the EnterNext PEA-PME 150 index from Euronext Paris

Download
Release
30.09.2020

VALBIOTIS publishes its 2020 half-year results and provides an update on its global strategic partnership with Nestlé Health Science, its strong financial visibility and the promising advances in its pipeline

Download
Release
21.09.2020

VALBIOTIS selected to present 3 studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD)

Download
Release
14.09.2020

VALBIOTIS receives US and European TOTUM-070 patent for reducing hypercholesterolemia

Download
Release
03.08.2020

Provision of the Registration Document (R.20-018) (in French)

Download
Release
31.07.2020

Half year report of the liquidity contract – July 2020 (in French)

Download
Release
28.07.2020

VALBIOTIS announces a cash position of €10.9M at 30 June 2020

Download
Release
17.07.2020

VALBIOTIS opens up its capital to a new shareholder: AMIRAL GESTION

Download